Neotropix, Inc., a biotechnology company, develops and commercializes systemically deliverable oncolytic viruses for the treatment of neuroendocrine cancers. It develops NTX010, a naturally-occurring virus that attacks and kills neuroendocrine cancers, such as small cell lung cancer, small cell carcinomas originating in other organs, carcinoid, neuroblastoma, and certain other neuroendocrine cancers. The company was founded in 2003 and is headquartered in Malvern, Pennsylvania.